Welcome to the Starpharma Investor Centre

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Update your
shareholder details

 

Download 
Annual Report

2023 Annual General Meeting

 

Register for email updates

 

 

Latest News & Announcements

Click here for news archive

Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results (ASX Announcement)

May 27th, 2024

Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.

Read More

Investor Webinar - Starpharma Business Update (22 May 2024)

May 24th, 2024

Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update. 

Starpharma’s CEO, Cheryl Maley, hosted the webinar, alongside the CFO and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP of Development and Regulatory Affairs, Dr Jeremy Paull.

Read More

 

Reports & Presentations

Click here for financial reports archive

Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results (ASX Announcement)

May 27th, 2024

Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.

Read More

Investor Webinar - Starpharma Business Update (22 May 2024)

May 24th, 2024

Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update. 

Starpharma’s CEO, Cheryl Maley, hosted the webinar, alongside the CFO and Company Secretary, Justin Cahill, VP of Business Development, Dr Tony Eglezos, and VP of Development and Regulatory Affairs, Dr Jeremy Paull.

Read More